Aragen Life Sciences, a global CDMO, has signed a definitive agreement to acquire Pune-based Intox Pvt.
The acquisition will expand the company’s integrated discovery and development platform for the pharmaceuticals, biotechnology, animal health and agrochemicals industries. It will also enable the company to conduct safety assessment studies from a Good Laboratory Practice (GLP)-certified facility for submission to regulatory agencies including the FDA, the European Medicines Agency (EMA), and others globally.
Intox is a pre-clinical contract research organisation (CRO) with its test facilities in Pune, India. It has reportedly conducted more than 15,000 GLP studies for global clients across pharmaceuticals, biopharmaceuticals, plant protection, nutraceuticals, and medical devices.
Manni Kantipudi, CEO, Aragen Life Sciences, said: “Intox’s experienced scientific team has an excellent reputation for its scientific rigor and subject matter expertise, and I am delighted to welcome them into the Aragen family. This acquisition is in strategic alignment with our long-term vision to be a ‘one-stop’ integrated discovery, development and manufacturing partner to our customers.”
Dr Narendra Deshmukh, co-founder and Director, Intox Pvt said: “With over two decades of expertise, Intox is one of the most reputed GLP facilities in the country, trusted for the high-quality data generated by our scientists, which has helped our customers receive approvals from national and global regulatory agencies such as USEPA, USFDA, European Commission amongst others.”
The acquisition will also expand Aragen’s footprint in India. It currently has research and manufacturing facilities at Hyderabad, Bengaluru and Vizag in India and a biologics facility in California, USA.
